132results about "Depsipeptide ingredients" patented technology

Apparatuses and methods for treating tumors. A method of treatment may include reducing the microvasculature of a region between a tumor and a lumen through or adjacent to the tumor (e.g., by administering radiation therapy targeting the tumor), isolating a segment of a lumen proximate to the tumor, and administering a dose of a chemotherapeutic agent to the segment.

Described are compositions and methods for treating pain and / or increasing opioid therapy efficacy and ameliorating opioid use disorder. The compositions and methods target Gαg / 11 signaling.

The invention provides application of a deacetylase inhibitor or a derivative thereof and application of a pharmaceutical composition, and belongs to the technical field of biology. The application of the deacetylase inhibitor or the pharmaceutically acceptable derivative thereof comprises the application of the deacetylase inhibitor for preparing a medicine for treating osteoporosis; wherein the deacetylase inhibitor is used for inducing histone acetylation in a cell nucleus. By inducing acetylation of histone in a cell nucleus, the differentiation direction of the bone marrow mesenchymal stem cells is accurately and efficiently controlled, and a treatment scheme for osteoporosis related diseases is developed.

The invention belongs to the field of biological medicine, and relates to application of an HDAC (histone deacetylase) inhibitor in treatment of liver cancer, in particular to application of the HDAC inhibitor in preparation of medicines for treating liver cancer, slowing down liver cancer progress and / or preventing liver cancer recurrence, a medicine composition for treating liver cancer, slowing down liver cancer progress and / or preventing liver cancer recurrence and a treatment method.

Provided are compositions that include a histone deacetylase inhibitor (HDACi) encapsulated in and / or otherwise associated with a nanoparticle. In some embodiments, the HDACi is romidepsin, vorinostat, belinostat, panobinostat, and / or chidamide. In some embodiments, the nanoparticle is a poly(D,L-lactide)-PEG-methyl ether (mPEG-PDLLA) nanopolymer. Also provided are methods for treating diseases, disorders, and / or conditions associated with sensitivity to histone deacetylase inhibitors, such as but not limited to tumors and / or cancers; and methods for inhibiting the growth, proliferation, and / or metastasis of a tumor and / or a cancer associated with sensitivity to histone deacetylase inhibitors by administering an effective amount of a composition as disclosed herein, which methods can optionally include administering at least one additional therapeutically active agent, such as but not limited to a chemotherapeutic agent.

Embodiments of the present invention relate to a novel compound of Formula (I)or stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, for use in treatment of infection caused by Gram-negative bacteria.

The present invention relates to a composition comprising tigolaner and, optionally endoparasiticidal agents, a method for its manufacture and its use as a medicament for controlling parasites. Compositions can include tigolaner and 1,2-isopropylideneglycerol, or the composition can include praziquantel, emodepside a solvent component, and tigolaner. The composition can be used in the treatment and / or prevention of parasite infections in animals.

The present invention provides a drug delivery carrier comprising a liposome modified with a cell-penetrating peptide and a positively charged polyamino acid as a polymer. The drug delivery carrier is used to prepare a pharmaceutical formulation in the form of a liposome complex with a particle size of 50 nm to 300 nm. The pharmaceutical formulation is prepared by mixing a physical complex consisting of a positively charged polyamino acid and one or more drug molecules with a liposome whose surface is modified with a cell-penetrating peptide. The pharmaceutical formulation can effectively transfect cells, particularly promoting drug absorption into the brain via intranasal administration, thereby improving the therapeutic efficacy of the drug.

The present invention relates to a composition comprising tigolaner and, optionally endoparasiticidal agents, a method for its manufacture and its use as a medicament for controlling parasites. Compositions can include tigolaner and 1,2-isopropylideneglycerol, or the composition can include praziquantel, emodepside a solvent component, and tigolaner. The composition can be used in the treatment and / or prevention of parasite infections in animals.

Provided are methods and compositions for the treatment of cancer. The methods comprise administering to a subject an HDAC inhibitor and an immunotherapeutic. In certain instances the immunotherapeutic is a chimeric antigen receptor T cell, an antibody or polypeptide that binds a checkpoint inhibitor, or a vaccine.

The present invention provides cyclic depsipeptide compounds of formula (I) and compositions comprising the compounds that are effective against parasites that harm animals. The compounds and compositions may be used for combating parasites in or on mammals and birds. The invention also provides for an improved method for eradicating, controlling and preventing parasite infestation in birds and mammals.

Described herein are methods useful for the treatment of cancers in a canine subject with a pharmaceutical compositions comprising HDAC inhibitors, Rapamycin, Dasatinib, Lapatinib, Trametinib, Vorinostat, Imatinib, Crizotinib, Sorafenib, and combinations thereof. Also described herein are methods for identification of subjects with cancers that will benefit from administration of the pharmaceutical compositions comprising HDAC inhibitors, Rapamycin, Dasatinib, Lapatinib, Trametinib, Vorinostat, Imatinib, Crizotinib, Sorafenib, and combinations thereof. In certain aspects, the methods described herein further comprise administering a therapeutically effective amount of at least one additional anti-cancer agent.

The present disclosure relates to methods for genetically subtyping peripheral T-cell lymphoma. TIFF2025506567000021.tif56128

Disclosed herein, are methods for treating, preventing or inhibiting a coronavirus infection or a disease or condition associated with a coronavirus infection. The methods can comprise administering to the subject one or more therapeutically effective doses of valproic acid and docosahexaenoic acid.

Disclosed herein are embodiments of a combination and / or composition for administration to animals. In some embodiments, the combination and / or composition can be administered to treat and / or prevent a disease in animals. In some embodiments, the combination and / or composition can be administered to promote animal health. In some embodiments, the combination comprises a composition comprising Yucca schidigera, Quillaja saponaria, and combinations thereof and a composition comprising an antimicrobial, an antibiotic, an anticoccidial, a vaccine, or combinations thereof. The combinations or compositions disclosed herein can also improve feed conversion rates in animals.

Embodiments of the disclosure include methods and compositions for treatment of cancer, autoimmune disorders, and / or infectious disease. In particular embodiments, antigen expression on target cells is increased with epigenetic modulators in conjunction with immune effector cells engineered to express a heterologous molecule that targets the target cells. In specific embodiments, the epigenetic modulators are used in conjunction with NK cells expressing a chimeric antigen receptor that targets a cancer antigen, an antigen associated with an autoimmune disorder, or an antigen associated with a pathogen.

Provided are methods and compositions for the treatment of cancer. The methods comprise administering to a subject an HDAC inhibitor and an immunotherapeutic agent. In certain instances the immunotherapeutic is an NK cell or a chimeric antigen receptor NK cell.

Disclosed are methods to stimulate intracellular mitophagy in a cell nucleus of a subject in need thereof, by administering to the subject an effective amount of a sterol regulatory element-binding protein (SREBP) signaling pathway activator that induces nuclear translocation of SREBP C-terminal regulatory domain into the cell nucleus.

Provided are methods and compositions for the treatment of cancer. The methods comprise administering to a subject an HDAC inhibitor and an immunotherapeutic agent. In certain instances the immunotherapeutic is an NK cell or a chimeric antigen receptor NK cell.

An external or topical formulation for treatment or prevention of infections involving body surfaces using a depsipeptide antibiotic drug such as lotilibcin having improved efficacy and safety is provided. The antibacterial effect of lotilibcin tested in infectious models is substantially enhanced by addition of boric acid in a low concentration of an additive level which does not produce any pharmacological activity by itself, thereby offering a formulation for external preparations having improved safety due to a decrease in dose, dosing period, and dosing frequency.

This method for producing a co-crystal containing a cyclic peptide and a compound having a melting point of 20 DEG C or higher comprises a step of bringing the cyclic peptide into contact with the compound and a solvent.

The present invention provides pharmaceutical compositions of teixobactin that are capable of preventing gelation of teixobactin. The pharmaceutical compositions comprise teixobactin and a pegylated phospholipid. The present invention also provides methods of preparing the pharmaceutical compositions of teixobactin and methods of treating a subject using the pharmaceutical compositions of teixobactin.

The present disclosure describes a novel method for decellularizing amphibian extracellular matrix to obtain isolated ECM that is substantially free of cellular and nuclear debris. The method includes washing the amphibian ECM in a solution containing one or more detergents, incubating the ECM with one or more proteases, and incubating the ECM with one or more nucleases. The present disclosure also describes various methods of using the isolated ECM.

Provided are a combination of an inositol phosphorylceramide synthase inhibitor and amphotericin B and use thereof. The use includes preparing a pharmaceutical composition, which includes an inositol phosphorylceramide synthetase inhibitor and amphotericin B or a salt thereof. Inositol phosphorylceramide is an important and conserved component of fungal plasma membranes. In the pharmaceutical composition according to an embodiment of the present disclosure, due to the presence of the inositol phosphorylceramide synthase inhibitor, the interaction between the inositol phosphorylceramide synthase inhibitor and amphotericin B not only enhances the inhibitory ability of the inositol phosphorylceramide synthase inhibitor on the synthesis of inositol phosphorylceramide in Cryptococcus, but also effectively reduces the dosage of amphotericin B and prolongs the half-life of amphotericin B, facilitating to reduce the adverse reactions of amphotericin B. The pharmaceutical composition exhibits superior fungicidal effect and safety compared to the currently used clinical combination of 5-fluorocytosine and amphotericin B.

The present disclosure describes a novel method for decellularizing amphibian extracellular matrix to obtain an isolated ECM that is substantially free of cellular and nuclear debris. The method includes washing the amphibian ECM in solutions containing one or more surfactants, incubating the ECM with one or more proteases, and incubating the ECM with one or more nucleases. The present disclosure also describes various methods of using the isolated ECM.

The present invention relates to the use of compounds in the treatment of autoimmune conditions, in particular in the treatment of rheumatoid arthritis.